Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.
IGM Biosciences, Inc. (IGMS) generates news primarily through its clinical-stage biotechnology activities and corporate transactions. The company has described itself as focused on developing engineered IgM-based therapeutic antibodies, including T cell engaging IgM antibodies, for cancer and autoimmune and inflammatory diseases. Its updates often cover progress in clinical trials, strategic shifts in its pipeline, collaboration developments and significant corporate events.
News items have detailed the advancement of key product candidates such as imvotamab, a CD20 x CD3 bispecific IgM T cell engager antibody studied in autoimmune indications including rheumatoid arthritis, systemic lupus erythematosus and idiopathic inflammatory myopathies, and IGM‑2644, a CD38 x CD3 T cell engager antibody in development for autoimmune diseases. Other releases have described clinical studies of aplitabart (also referred to as IGM‑8444), a death receptor 5 agonist evaluated in combination regimens for metastatic colorectal cancer, along with enrollment milestones and trial design features.
Corporate news has included a strategic pivot to focus exclusively on autoimmunity, with an associated pipeline transformation and workforce changes, followed by a later decision to halt further development of imvotamab and IGM‑2644 for autoimmune diseases and to explore internal options and strategic alternatives. IGM Biosciences has also issued announcements about its exclusive worldwide collaboration agreement with Sanofi on IgM antibody agonists for immunology and inflammation targets and other collaborations with biotechnology partners.
A major development in the company’s news flow is the announcement of a definitive merger agreement under which Concentra Biosciences, LLC will acquire IGM Biosciences through a cash tender offer and subsequent merger, with IGM Biosciences becoming a wholly owned subsidiary of Concentra. For readers following IGMS, the news stream provides context on the evolution of the company’s IgM antibody pipeline, its strategic decisions and the transaction that led to its acquisition.
IGM Biosciences announces the initiation of a Phase 1 clinical trial for IGM-7354, an IL-15/IL-15R IgM antibody targeting solid and hematologic malignancies. The trial aims to assess the safety, pharmacokinetics, and immune cell proliferation in patients with relapsed or refractory solid tumors. If successful, the company may advance to combination studies with T cell engaging antibodies and CAR-T cells as early as 2024. The development represents a significant milestone, focusing on enhancing immune activity in the tumor microenvironment while minimizing systemic toxicity. Collaboration with Sanofi is expected to drive further advancements.
Medivir AB (Nasdaq Stockholm: MVIR) announced its participation in the Redeye Fight Cancer Day on January 19, 2023. CEO Jens Lindberg will present the ongoing clinical study of fostroxacitabine bralpamide (fostrox) at 13.35 CET. The presentation will be broadcast live and can be accessed through the event page. Additionally, it will be available later on Medivir's website. Medivir focuses on developing innovative cancer treatments for unmet medical needs, particularly targeting liver cancer. The company’s drug fostrox aims to minimize side effects while effectively treating cancer cells. Medivir's shares are listed under the ticker MVIR.
IGM Biosciences announced promising Phase 1 data for IGM-8444 in metastatic colorectal cancer, demonstrating an encouraging safety profile when combined with FOLFIRI chemotherapy. The trial revealed multiple confirmed patient responses, with some patients achieving substantial tumor shrinkage. Median progression-free survival was reported at 5.5 months for certain patient cohorts. Following these results, a randomized trial in second-line patients is set to begin in Q1 2023, aiming to further evaluate the effectiveness of IGM-8444 alongside FOLFIRI and bevacizumab.
IGM Biosciences, a clinical-stage biotechnology company, announced that CEO Fred Schwarzer will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:15 p.m. PST in San Francisco. The event will be available via a live webcast on the company's website, with a replay accessible for 30 days.
The company focuses on developing IgM antibodies for treating cancer, infectious diseases, and autoimmune disorders, leveraging a collaboration with Sanofi to develop IgM antibody agonists.
IGM Biosciences presented promising preclinical data for IGM-2644 and IGM-2537 at the 2022 ASH Annual Meeting. Both bispecific IgM antibodies showed potential anti-tumor activity with favorable safety profiles. IGM-2644 demonstrated superior cytotoxicity against myeloma cells compared to traditional IgG antibodies and is set for a Phase 1 trial in early 2023. Similarly, IGM-2537 displayed potent activity against acute myeloid leukemia with minimal cytokine release, with IND filing anticipated in 2023. Biomarker data for imvotamab also indicated efficacy in low CD20 expressing tumors.
IGM Biosciences, a clinical-stage biotechnology company focused on IgM antibodies, announced that CEO Fred Schwarzer will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on December 8, 2022, at 2:45 p.m. EST.
The event will be webcast live on the company’s website, with a replay available for 90 days. IGM is dedicated to developing innovative therapies for cancer and other diseases, leveraging its IgM antibody technology, which offers superior binding capabilities compared to traditional antibodies.
IGM Biosciences, a clinical-stage biotechnology firm focusing on IgM antibodies, announced that CEO Fred Schwarzer will participate in several investor conferences. The events include:
- Stifel Healthcare Conference on November 15 in New York
- Jefferies London Healthcare Conference on November 17 in London
- Evercore ISI HealthCONx Conference on December 1 (virtual)
Live webcasts will be available on the Company’s website and will remain archived for 90 days post-event.
IGM Biosciences (Nasdaq: IGMS) reported its Q3 2022 financial results, showing a net loss of $58 million, unchanged at $1.32 per share. Cash and investments rose to $469.1 million compared to $229.5 million at the end of 2021. Collaboration revenue reached $0.3 million, up from zero in Q3 2021. The company is progressing in its T cell engager portfolio, with promising data from the Phase 1 trial of imvotamab, where 7 of 8 complete response patients remain tumor-free after a year. IGM aims for a Phase 2 update on imvotamab in Q1 2023.
IGM Biosciences and ADC Therapeutics have partnered to evaluate a combination therapy for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Their collaboration focuses on IGM's bispecific antibody, imvotamab, combined with ADC's ZYNLONTA®. A Phase 1 trial is expected to start in Q1 2023. Preliminary data shows imvotamab achieved a 50% complete response rate in prior studies, with manageable safety profile.
IGM Biosciences and ADC Therapeutics have formed a clinical trial collaboration to examine a combination therapy for relapsed/refractory B cell non-Hodgkin’s lymphoma (NHL). This partnership will evaluate IGM’s imvotamab, a bispecific antibody, alongside ADC’s ZYNLONTA®, an antibody-drug conjugate. The Phase 1 trial is slated to commence in Q1 2023. Previous data indicated a 50% complete response rate for imvotamab at optimal dosing, with manageable safety profiles. Both companies aim to address significant unmet medical needs in lymphoma treatments.